BCIQ Profiles

Company Profile ReportTarget Profile Report

Andera looks early for cancer immunotherapy

How Grey Wolf's A round helped Andera diversify its cancer immunotherapy portfolio

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey Wolf, announced with the

Read the full 395 word article

How to gain access

Continue reading with a
two-week free trial.